About Lixoft
Lixoft is a company based in Antony (France) founded in 2011 was acquired by Simulations Plus in April 2020. Lixoft offers products and services including MonolixSuite, PKanalix, Monolix, and Simulx. Lixoft operates in a competitive market with competitors including Insitro, HotSpot Therapeutics, Certara, TOLREMO therapeutics and Inpharmatica, among others.
- Headquarter Antony, France
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Simulations Plus
(Apr 02, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lixoft
Lixoft offers a comprehensive portfolio of products and services, including MonolixSuite, PKanalix, Monolix, and Simulx.
Software suite for drug development analysis and simulation tools.
Tool for non-compartmental and compartmental analysis in pharmacometrics.
Application for parameter estimation in non-linear mixed effect models.
Platform for clinical trial pharmacometrics modeling and scenarios.
Funding Insights of Lixoft
Detailed funding history for Lixoft
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Lixoft
Lixoft has secured backing from 1 investor. Prominent investors backing the company include Simulations Plus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Simulation software is developed for chemoinformatics and drug discovery.
|
Locked | Locked | Locked |
Investor details for Lixoft
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lixoft
Investment portfolio details for Lixoft
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lixoft
Detailed financials for Lixoft
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lixoft Comparisons
Peer comparison for Lixoft
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lixoft
Lixoft operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, HotSpot Therapeutics, Certara, TOLREMO therapeutics and Inpharmatica, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Developer of a platform for protein function analysis
|
|
| Locked | Locked | Locked |
Provider of a platform for in silico drug discovery and consulting services
|
|
| Locked | Locked | Locked |
Anti-cancer small molecules are developed to target drug resistance pathways.
|
|
| Locked | Locked | Locked |
Developer of predictive informatics based platform for drug discovery
|
|
| Locked | Locked | Locked |
Immune system-based drugs are discovered via biological data analytics.
|
Detailed competitors of Lixoft
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lixoft
Complete news archive for Lixoft
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lixoft
Lixoft was founded in 2011.
Lixoft is headquartered in Antony, France. It is registered at Antony, Ile-de-france, France.
The company was founded in 2011 and is based in Antony, France. Software solutions for model-based drug development and population analytics are provided, focusing on the pharmacometrics sector. Key products include Monolix for parameter estimation in non-linear mixed effects models, Mlxplore for visualization and exploration, Simulx for clinical trial simulation, and Datxplore for pre-data analysis. Consultancy, training, and support services are also offered.
Lixoft's top competitors include Insitro, HotSpot Therapeutics and Certara.
Lixoft offers MonolixSuite, PKanalix, Monolix, and Simulx.
Lixoft has 1 investor. Key investors include Simulations Plus.